CERS1 (Ceramide Synthase 1), also known as Lass1 (longevity assurance gene 1), is a critical enzyme in the biosynthesis of ceramides, a fundamental class of sphingolipids essential for cellular membrane structure and signaling functions. Located on chromosome 19p13.3, this gene encodes a 422-amino acid protein that catalyzes the N-acylation of sphingoid bases to produce ceramides, the central hub of sphingolipid metabolism[1].
CERS1 exhibits particular importance in the nervous system due to its chain-length specificity—predominantly producing C18-ceramides, which are the predominant ceramide species in the brain. This enzyme has been increasingly recognized for its involvement in neurodegenerative diseases, particularly Parkinson's disease, where genetic variants and altered ceramide metabolism contribute to pathogenesis. Additionally, CERS1 plays essential roles in neuronal survival, myelin formation, and the regulation of apoptosis, making it a significant node in the intersection of lipid biology and neurodegeneration[2][3].
| Feature | Details |
|---|---|
| Gene Symbol | CERS1 (LASS1) |
| Full Name | Ceramide Synthase 1 / Longevity Assurance 1 |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 24145 |
| OMIM | 606919 |
| Ensembl ID | ENSG00000154188 |
| UniProt | Q8IV08 |
| Protein Length | 422 amino acids |
| Molecular Weight | ~48 kDa |
CERS1 is a multi-pass transmembrane enzyme localized primarily to the endoplasmic reticulum[4]:
The enzyme requires CoA as a cofactor for the acylation reaction and exhibits specificity for different sphingoid base substrates, with CERS1 preferring sphingosine to produce C18-ceramides.
CERS1 demonstrates unique chain-length specificity:
| Product | Carbon Length | Brain Abundance | Cellular Function |
|---|---|---|---|
| C18-ceramide | 18:0 | Highest | Neuronal signaling, myelin |
| C20-ceramide | 20:0 | Moderate | Specific signaling roles |
| C16-ceramide | 16:0 | Low (CERS2) | Ubiquitous |
| C14-ceramide | 14:0 | Very low | Specific contexts |
CERS1 catalyzes the fundamental reaction of ceramide synthesis:
Sphingosine + Acyl-CoA → Ceramide + CoA
This reaction occurs in the endoplasmic reticulum and represents the committed step in sphingolipid biosynthesis. Ceramide serves as the precursor for:
CERS1 sits at a critical node in sphingolipid metabolism[5][6]:
1. Membrane Structure and Organization
2. Apoptosis Regulation
3. Autophagy Modulation
4. Neuroprotection
Ceramide functions as a bioactive lipid messenger:
1. Receptor Signaling
2. Protein Kinase Regulation
3. Mitochondrial Effects
Ceramide induces autophagy through multiple mechanisms:
CERS1 has emerged as a significant player in Parkinson's disease pathogenesis[3:1][9][10]:
1. Genetic Associations
2. Ceramide Metabolism Dysregulation
3. Alpha-Synuclein Interaction
4. Mitochondrial Function
5. Neuroinflammation
In ALS, CERS1 contributes through[11]:
1. Motor Neuron Vulnerability
2. Lipid Metabolism Dysregulation
3. Protein Aggregation
CERS1 is directly implicated in certain forms of NCL:
1. Ceramide Accumulation
2. Autophagy-Lysosome Pathway
Though less directly studied, CERS1 has relevance to AD[12][13]:
| Brain Region | Expression Level | Notes |
|---|---|---|
| Substantia Nigra | High | Dopaminergic neurons |
| Hippocampus | High | CA1-CA3, dentate gyrus |
| Cerebral Cortex | High | Pyramidal neurons |
| Cerebellum | Moderate-High | Purkinje cells |
| Spinal Cord | High | Motor neurons |
| Corpus Callosum | High | Oligodendrocytes |
| Enzyme/Protein | Interaction | Function |
|---|---|---|
| CERS2 | Paralog | C16-ceramide production |
| CERS3 | Paralog | Skin/testis specific |
| DEGS1 | Downstream | Dihydroceramide desaturase |
| SGPP1 | Downstream | Sphingosine-1-phosphate phosphatase |
| SMPD1 | Downstream | Acid sphingomyelinase |
Modulating CERS1 offers potential therapeutic strategies[9:1][15]:
1. Ceramide Analog Therapy
2. Enzyme Activity Modulation
3. Downstream Pathway Targeting
The balance between ceramide (pro-death) and S1P (pro-survival) determines neuronal fate:
| Factor | Ceramide | Sphingosine-1-P |
|---|---|---|
| Effect | Pro-apoptotic | Pro-survival |
| Signaling | JNK, PKCzeta | S1PR1-5 |
| Autophagy | Induction | Inhibition |
| Inflammation | Pro-inflammatory | Anti-inflammatory |
Neurodegenerative diseases feature altered lipid composition:
CERS1 deficiency affects:
Teigell M, et al. CERS1 deficiency leads to neurodegeneration in mice. Human Molecular Genetics. 2013. ↩︎
Vasili E, et al. Ceramide metabolism in neurodegenerative diseases. Biochimica et Biophysica Acta. 2019. ↩︎
Ourier-Leroy C, et al. CERS1 variants in Parkinson's disease. Movement Disorders. 2018. ↩︎ ↩︎
Hahn JS, et al. Ceramide metabolism in the brain. Progress in Lipid Research. 2013. ↩︎
Maceyka M, et al. Sphingolipid metabolites in disease. Physiological Reviews. 2012. ↩︎
Hofmann K, et al. Ceramide synthases in lipid signaling and disease. Cellular and Molecular Life Sciences. 2020. ↩︎
Morales A, et al. Ceramide as a regulator of autophagy. Biochimica et Biophysica Acta. 2012. ↩︎
Gomez L, et al. Ceramide and apoptosis. Cell Death and Differentiation. 2010. ↩︎
Kim H, et al. Targeting ceramide metabolism in Parkinson's disease. Cellular and Molecular Neurobiology. 2021. ↩︎ ↩︎
Saxena S, et al. Ceramide in Parkinson's disease models. Journal of Parkinson's Disease. 2019. ↩︎
Ben-David O, et al. Ceramide synthases in neuronal function and survival. Journal of Neurochemistry. 2011. ↩︎
Novince CM, et al. Ceramide biology in Alzheimer's disease. Nature Reviews Neurology. 2020. ↩︎
Levy M, et al. Sphingolipid metabolism in Alzheimer's disease. Molecular Neurobiology. 2019. ↩︎
Fabri J, et al. CERS1 and myelin formation. GLIA. 2021. ↩︎
Cowart LA, et al. Targeting ceramide metabolism for neuroprotection. Advances in Neurobiology. 2019. ↩︎